Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06572384 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
A Phase 3 study of Lung Diseases, Interstitial, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 440
- Enrollment target
- 20
- Study locations
NCT06572384 is a Phase 3 study of Lung Diseases, Interstitial that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 440 participants, below the 12,465-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06572384, a Phase 3 study of Lung Diseases, Interstitial, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 440 participants
- Enrollment target
- 20
- Study locations
Study Summary
Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Belimumab
Study Locations (20)
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - San Francisco
- GSK Investigational Site - Upland
Other
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Ciudad Autonoma Buenos Aires
New York
- GSK Investigational Site - New York
- GSK Investigational Site - New York
- GSK Investigational Site - Potsdam
Florida
- GSK Investigational Site - Gainesville
- GSK Investigational Site - Naples
Texas
- GSK Investigational Site - Houston
- GSK Investigational Site - Temple
Missouri
- GSK Investigational Site - St Louis
North Carolina
- GSK Investigational Site - Durham
Pennsylvania
- GSK Investigational Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2028-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06572384
The ClinicalTrials.gov registry entry for NCT06572384 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,465-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (96% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Diseases, Interstitial appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06572384 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Other, New York.
Frequently Asked Questions
What is clinical trial NCT06572384 about?
NCT06572384 is a clinical study titled "A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease". Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the ...
What is the current status of trial NCT06572384?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 440 participants. The study started on 2024-09-11. Estimated completion is 2028-12-13.
What conditions does trial NCT06572384 study?
This clinical trial studies the following conditions: Lung Diseases, Interstitial.
What interventions are being tested in trial NCT06572384?
The interventions under investigation include: Placebo (OTHER), Belimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06572384?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06572384 being conducted?
This trial has 20 study locations across California, Florida, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases, Interstitial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
COMPLETED · Phase 3
-
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RECRUITING
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
-
Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease
RECRUITING · Phase 1
-
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
RECRUITING · NA
-
Cough Capture as a Portal Into the Lung
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.